Status:
COMPLETED
8-Week Atopic Dermatitis (AD) Treatment Study
Lead Sponsor:
Procter and Gamble
Conditions:
Atopic Dermatitis Eczema
Eligibility:
All Genders
12-65 years
Phase:
PHASE3
Brief Summary
This is a study to investigate the clinical effectiveness of the Sponsor's experimental cream treatment on eczema as measured by visual grading of SCORAD (scoring of atopic dermatitis).
Detailed Description
This will be a 9-week, randomized, double blind, parallel comparison study consisting of a 1-week washout phase followed by an 8-week treatment phase. This study will be executed by one clinical resea...
Eligibility Criteria
Inclusion
- Is a generally healthy, male or female, 12-65 years old, inclusive;
- Diagnosis of moderate or greater Atopic Dermatitis as determined by SCORAD (SCORAD \>=25);
- Is able to read and understand instructions in English.
Exclusion
- Is currently participating or has participated in another interventional clinical study in the past 2 weeks;
- Currently or has been diagnosed or treated for cancer in the past 5 years;
- Requires any topical or systemic medications that could affect the course of their atopic dermatitis during the study period (except inhaled steroids and/or stable antihistamines for asthma or allergies);
- Has used systemic treatments that could affect AD within 30 days or 5 half- lives. (i.e. retinoids, methotrexate, cyclosporine, hydroxycarbamide (hydroxyurea), azathioprine and oral/injectable corticosteroids);
- Has a known hypersensitivity to any corticosteroid creams;
- Has been diagnosed with any allergies to Oat or derivatives;
- Has any active infections or has used antibiotics in the past 7 days;
- Has any physical attributes or skin conditions that might interfere with the clear visual or instrumental assessments.(i.e. cuts, sunburn, birth marks, tattoos, extensive scarring, excessive hair growth or acne);
- Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus rheumatoid arthritis) which could place the subject at risk or interfere with the accuracy of the study results;
- Has used any immunosuppressant drugs or immunotherapy within the past 30days or 5 half-lives;
- Is an employee of the sponsor company or clinical testing site;
- Is diabetic;
- Presents with the presence of an active or chronic allergic reaction as evidenced by an irregular white cell count determined by eosinophils \> 0.3 X 109/L at Screening Visit;
- Is planning a trip to a sunny climate, to use tanning booths or use other UV sources throughout the course of this study;
- Has a history of hypersensitivity to any substance in investigational preparation or to Desonide;
- Has any clinically significant medical condition or laboratory abnormality that would, in the opinion of the Investigator, put the patient at undue risk or interfere with the interpretation of the study results;
- Is dependent on oral medication for any skin disease/condition or could not, in the opinion of the Investigator tolerate the restriction of discontinuing the medicine as required in this study;
- Is currently pregnant or lactating or planning to become pregnant in the next 6 months;
- Has other skin conditions that might interfere with AD diagnosis and/or evaluation (i.e. psoriasis current active viral, bacterial and fungal skin infections) as assessed by the Investigator;
- Any other condition or factor the Investigator or their duly assigned representative believes may affect the ability of the subject to complete the study or the interpretation
Key Trial Info
Start Date :
November 27 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 18 2018
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT03386032
Start Date
November 27 2017
End Date
August 18 2018
Last Update
December 17 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Research, LLC
Raleigh, North Carolina, United States, 27612
2
WR (Wake Research) ClinSearch
Chattanooga, Tennessee, United States, 37421